These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27605156)

  • 1. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
    García-Sanz R; Corchete LA; Alcoceba M; Chillon MC; Jiménez C; Prieto I; García-Álvarez M; Puig N; Rapado I; Barrio S; Oriol A; Blanchard MJ; de la Rubia J; Martínez R; Lahuerta JJ; González Díaz M; Mateos MV; San Miguel JF; Martínez-López J; Sarasquete ME;
    Hematol Oncol; 2017 Dec; 35(4):746-751. PubMed ID: 27605156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden.
    Nahi H; Walinder G; Patel V; Qu Y; Levine A; Majer I; Kutikova L; Hellqvist Franck E; Svensson MK; Hansson M
    Acta Haematol; 2021; 144(5):519-527. PubMed ID: 33631745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic reviews with meta-analyses.
    Aguiar PM; de Mendonça Lima T; Colleoni GWB; Storpirtis S
    Crit Rev Oncol Hematol; 2017 May; 113():195-212. PubMed ID: 28427509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.
    Magrangeas F; Kuiper R; Avet-Loiseau H; Gouraud W; Guérin-Charbonnel C; Ferrer L; Aussem A; Elghazel H; Suhard J; Sakissian H; Attal M; C Munshi N; Sonneveld P; Dumontet C; Moreau P; van Duin M; Campion L; Minvielle S
    Clin Cancer Res; 2016 Sep; 22(17):4350-4355. PubMed ID: 27060151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy-related peripheral neuropathy in multiple myeloma patients.
    Morawska M; Grzasko N; Kostyra M; Wojciechowicz J; Hus M
    Hematol Oncol; 2015 Dec; 33(4):113-9. PubMed ID: 25399783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
    Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
    Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
    Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
    Wang J; Udd KA; Vidisheva A; Swift RA; Spektor TM; Bravin E; Ibrahim E; Treisman J; Masri M; Berenson JR
    Support Care Cancer; 2016 Jul; 24(7):3105-10. PubMed ID: 26902977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
    Mahmoudpour SH; Bandapalli OR; da Silva Filho MI; Campo C; Hemminki K; Goldschmidt H; Merz M; Försti A
    BMC Cancer; 2018 Aug; 18(1):820. PubMed ID: 30111286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
    El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
    Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
    J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
    Johnson DC; Corthals SL; Walker BA; Ross FM; Gregory WM; Dickens NJ; Lokhorst HM; Goldschmidt H; Davies FE; Durie BG; Van Ness B; Child JA; Sonneveld P; Morgan GJ
    J Clin Oncol; 2011 Mar; 29(7):797-804. PubMed ID: 21245421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk Factors and Outcomes of Thalidomide-induced Peripheral Neuropathy in a Pediatric Inflammatory Bowel Disease Cohort.
    Bramuzzo M; Stocco G; Montico M; Arrigo S; Calvi A; Lanteri P; Costa S; Pellegrino S; Magazzù G; Barp J; Ghione S; Lionetti P; Zuin G; Fontana M; Di Chio T; Maggiore G; Lazzerini M; Lucafò M; Udina C; Pellegrin MC; Chicco A; Carrozzi M; Decorti G; Ventura A; Martelossi S
    Inflamm Bowel Dis; 2017 Oct; 23(10):1810-1816. PubMed ID: 28817461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
    Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
    Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison and development of machine learning for thalidomide-induced peripheral neuropathy prediction of refractory Crohn's disease in Chinese population.
    Mao J; Chao K; Jiang FL; Ye XP; Yang T; Li P; Zhu X; Hu PJ; Zhou BJ; Huang M; Gao X; Wang XD
    World J Gastroenterol; 2023 Jun; 29(24):3855-3870. PubMed ID: 37426324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
    Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
    J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
    Banach M; Jurczyszyn A; Skotnicki A
    Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.